February 18, 2021    Rome, Italy

Webinar on COVID-19 Vaccination

February 18, 2021

Webinar on COVID-19 Vaccination

COVID-19 Vaccines and Current Research and Development Status

Briefly Know About This Event

COVID-19 is a platform for, (Doctors, physicians, research scholars, students, and business, pharma professionals) to expose their research work, to Share their knowledge in COVID-19 Vaccination. It is an occasion to interact with associates across the globe focused on learning about COVID-19 Vaccines and current research and development status. World prominent speakers, the most recent therapies and the recent modernize in COVID-19 Vaccines are trademarks of this webinar. Major scientific sessions of  COVID-19 Webinar are COVID-19, COVID-19 and Impact on Healthcare, Infection Control Procedures, Vaccine Research & Development, COVID-19 case reports and clinical trials ,  COVID-19 risk factors and prevention and this Webinar will be attracting leading researches and decision makers in their field, principal investigators, and business professionals for sharing knowledge and research globally.

Webinar on COVID-19 Vaccination will be hosted on February 18, 2021 at 09:00 AM (GMT+4). Panel of speakers will be delivering their presentations on their recent research related to COVID-19 Vaccination. The current state of knowledge, its impact on the future will be discussed in detail. Longdom  invites all experts to be part of this webinar series and make it a perfect platform for knowledge sharing and networking.


Coronavirus illness 2019 (COVID-19) is an irresistible ailment brought about by serious intense respiratory disorder coronavirus 2 (SARS-CoV-2). The illness was first distinguished in December 2019 in Wuhan, the capital of China's Hubei territory, and has since spread universally, bringing about the continuous 2019–20 coronavirus pandemic. Common indications incorporate fever, hack and brevity of breath. Different manifestations may incorporate exhaustion, muscle torment, looseness of the bowels, sore throat, loss of smell and stomach torment. While most of cases bring about gentle indications, some advancement to viral pneumonia and multi-organ disappointment.

The infection is for the most part spread during close contact and by little beads created when those contaminated hack, wheeze or talk. These little beads might be delivered during breathing; however the infection isn't for the most part airborne. People may likewise get tainted by contacting a sullied surface and afterward their face. The infection can get by on surfaces for as long as 72 hours. It is generally infectious during the initial three days after beginning of side effects, anyway it might be conceivable to spread the infection before side effects show up and in later phases of the sickness. The time from presentation to beginning of side effects is by and large somewhere in the range of 2 and 14 days, with a normal of 5 days. The standard technique for conclusion is by ongoing opposite interpretation polymerase chain response (rRT-PCR) from a nasopharyngeal swab.The contamination can likewise be analyzed from a mix of side effects, hazard factors and a chest CT examine demonstrating highlights of pneumonia.

Effective implementation of measures like closing down schools, universities, workplaces, and mass get-togethers notwithstanding social separating, could diminish the quantity of cases fundamentally and hinder its encouraging two-three months sooner.

The model took a gander at adequacy with changing degrees of isolate. It can extend on essentially at low levels, for example, 20 percent isolate. The effect on development starts to set in when 50 percent or a greater amount of contaminated people are disengaged asqto forestall spread.

Infection control deals with procedures and activities which bring to prevent or reduce the risk of transmission of infectious diseases. It is mainly works in a clinical setting or working in certain laboratories are at risk of occupational exposure to blood borne pathogens including hepatitis B (Hep B), hepatitis C (Hep C) and human immune deficiency virus (HIV) as well as occupational exposure to a range of microbiological agents. Standard analysis is the work practices needed to achieve a major level of infection control and prevention. The use of common precautions aims to reduce, and to eliminate the adequate risk of transmission of infection, particularly those caused by blood borne viruses. Microorganisms are present on hands (resident flora) or acquired during healthcare activities (transient flora). In Particular hand hygiene is to reduce the number of microorganisms on your hands, particularly transient flora which may present the greater risk for infection transmission.

Severe acute respiratory syndrome


West nile fever

Smallpox and other pox viruses

Vaccine Development is an activity that focuses on a variety of technological initiatives and applied research, which enhance and promote improved systems and practices for vaccine safety. In the past year, the unprecedented Ebola disease outbreak galvanized research and industry response and as we continue to search for solutions, we must review the lessons learned in order to overcome the current challenges. Vaccines development is a long, complex process, often lasting 10-15 years and involving a combination of public and private involvement. The current system for developing, testing, and regulating vaccines developed during the 20th century as the groups involved standardized their procedures and regulations.

Basic Vaccinology

Vaccines discovery, development & formulation

Vaccine clinical trials

Vaccine Management & Quality Assurance

COVID-19 studies listed on the World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP). Information in the WHO ICTRP comes from clinical trial databases maintained by other countries or regions of the world. COVID-19 studies listed on ClinicalTrials.gov are not included in the list below, but can be found using our search for COVID-19.

COVID-19 is a new disease. Currently there are limited data and information about the impact of underlying medical conditions and whether they increase the risk for severe illness from COVID-19. Based on what we know at this time, people with the following conditions might be at an increased risk for severe illness from COVID-19.


Although there is no vaccine available to prevent COVID-19, you can take steps to reduce your risk of infection. WHO and CDC recommend following these precautions for avoiding COVID-19:

  • Avoid large events and mass gatherings.
  • Avoid close contact (within about 6 feet, or 2 meters) with anyone who is sick or has symptoms.
  • Stay home as much as possible and keep distance between yourself and others (within about 6 feet, or 2 meters), especially if you have a higher risk of serious illness. Keep in mind some people may have COVID-19 and spread it to others, even if they don't have symptoms or don't know they have COVID-19.
  • Wash your hands often with soap and water for at least 20 seconds, or use an alcohol-based hand sanitizer that contains at least 60% alcohol.
  • Cover your mouth and nose with your elbow or a tissue when you cough or sneeze. Throw away the used tissue. Wash your hands right away.
  • Avoid touching your eyes, nose and mouth.
  • Avoid sharing dishes, glasses, towels, bedding and other household items if you're sick.
  • Clean and disinfect high-touch surfaces, such as doorknobs, light switches, electronics and counters, daily.
  • Stay home from work, school and public areas if you're sick, unless you're going to get medical care. Avoid public transportation, taxis and ride-sharing if you're sick.

Our Brilliant Speakers

LONGDOM conferences speaker bureau map future challenges through ideation sessions by designing and validating new ideas with end users by placing right speakers in front of right audience at the right time.

What Client's Say

We let our ground-breaking work and our amazing clients speak for us…… LONGDOM conferences

Speakers Interview